L Antigen Family Member 3 Serves As a Prognostic Biomarker for the Clinical Outcome and Immune Infiltration in Skin Cutaneous Melanoma

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2021 Apr 8

PMID 33829062

Citations 4

Authors

Jingjing Song

Cong Jin

Endong Chen

Xubin Dong

Libin Zhu

Affiliations

Soon will be listed here.

Abstract

L Antigen Family Member 3 (LAGE3) is an important RNA modification-related protein. Whereas few studies have interrogated the LAGE3 protein, there is limited data on its role in tumors. Here, we analyzed and profiled the LAGE3 protein in skin cutaneous melanoma (CM) using TCGA, GTEx, or GEO databases. Our data showed an upregulation of LAGE3 in melanoma cell lines compared to normal skin cell lines. Besides, the Kaplan-Meier curves and Cox proportional hazard model revealed that LAGE3 was an independent survival indicator for CM, especially in metastatic CM. Moreover, LAGE3 was negatively associated with multiple immune cell infiltration levels in CM, especially CD8 T cells in metastatic CM. Taken together, our study suggests that LAGE3 could be a potential prognostic biomarker and might be a potential target for the development of novel CM treatment strategies.

Citing Articles

DIRAS2 Is a Prognostic Biomarker and Linked With Immune Infiltrates in Melanoma.

Xue W, Zhu H, Liu H, He H Front Oncol. 2022; 12:799185.

PMID: 35651810 PMC: 9149220. DOI: 10.3389/fonc.2022.799185.

Analysis of L Antigen Family Member 3 as a Potential Biomarker and Therapeutic Target Associated With the Progression of Hepatocellular Carcinoma.

Chen Q, Lu X, Xie J, Ma N, Xu W, Zhang Z Front Oncol. 2022; 12:813275.

PMID: 35433409 PMC: 9008773. DOI: 10.3389/fonc.2022.813275.

Correlation of LAGE3 with unfavorable prognosis and promoting tumor development in HCC via PI3K/AKT/mTOR and Ras/RAF/MAPK pathways.

Li Y, Xiong H BMC Cancer. 2022; 22(1):298.

PMID: 35313850 PMC: 8939149. DOI: 10.1186/s12885-022-09398-3.

LAGE3 promoted cell proliferation, migration, and invasion and inhibited cell apoptosis of hepatocellular carcinoma by facilitating the JNK and ERK signaling pathway.

Xing Y, Liu Y, Qi Z, Liu Z, Wang X, Zhang H Cell Mol Biol Lett. 2021; 26(1):49.

PMID: 34837962 PMC: 8903694. DOI: 10.1186/s11658-021-00295-4.

References

Uhlen M, Fagerberg L, Hallstrom B, Lindskog C, Oksvold P, Mardinoglu A . Proteomics. Tissue-based map of the human proteome. Science. 2015; 347(6220):1260419. DOI: 10.1126/science.1260419. View

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu J . TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017; 77(21):e108-e110. PMC: 6042652. DOI: 10.1158/0008-5472.CAN-17-0307. View

Dong X, Gu D, Wang O, Ye Z . LAGE3 correlates with tumorigenic immune infiltrates in the clear cell renal cell carcinoma microenvironment. Int Immunopharmacol. 2020; 87:106793. DOI: 10.1016/j.intimp.2020.106793. View

Talantov D, Mazumder A, Yu J, Briggs T, Jiang Y, Backus J . Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res. 2005; 11(20):7234-42. DOI: 10.1158/1078-0432.CCR-05-0683. View

Cirenajwis H, Ekedahl H, Lauss M, Harbst K, Carneiro A, Enoksson J . Molecular stratification of metastatic melanoma using gene expression profiling: Prediction of survival outcome and benefit from molecular targeted therapy. Oncotarget. 2015; 6(14):12297-309. PMC: 4494939. DOI: 10.18632/oncotarget.3655. View

Braun D, Rao J, Mollet G, Schapiro D, Daugeron M, Tan W . Mutations in KEOPS-complex genes cause nephrotic syndrome with primary microcephaly. Nat Genet. 2017; 49(10):1529-1538. PMC: 5819591. DOI: 10.1038/ng.3933. View

Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov J, Tamayo P . The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2016; 1(6):417-425. PMC: 4707969. DOI: 10.1016/j.cels.2015.12.004. View

Begik O, Lucas M, Liu H, Ramirez J, Mattick J, Novoa E . Integrative analyses of the RNA modification machinery reveal tissue- and cancer-specific signatures. Genome Biol. 2020; 21(1):97. PMC: 7204298. DOI: 10.1186/s13059-020-02009-z. View

Spranger S, Spaapen R, Zha Y, Williams J, Meng Y, Ha T . Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013; 5(200):200ra116. PMC: 4136707. DOI: 10.1126/scitranslmed.3006504. View

10.

Kanhere A, Hertweck A, Bhatia U, Gokmen M, Perucha E, Jackson I . T-bet and GATA3 orchestrate Th1 and Th2 differentiation through lineage-specific targeting of distal regulatory elements. Nat Commun. 2012; 3:1268. PMC: 3535338. DOI: 10.1038/ncomms2260. View

11.

Dong X, Song J, He M, Sun J, Tao E, Zhang X . Identification of the prognostic and immunotherapeutic potential of L antigen family member 3 in malignant pleural mesothelioma. Clin Transl Med. 2020; 10(7):e207. PMC: 7689948. DOI: 10.1002/ctm2.207. View

12.

Racle J, de Jonge K, Baumgaertner P, Speiser D, Gfeller D . Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. Elife. 2017; 6. PMC: 5718706. DOI: 10.7554/eLife.26476. View

13.

Dong X, Lv S, Zhang X, Hao R . Upregulation of LAGE3 correlates with prognosis and immune infiltrates in colorectal cancer: A bioinformatic analysis. Int Immunopharmacol. 2020; 85:106599. DOI: 10.1016/j.intimp.2020.106599. View

14.

Sturm G, Finotello F, Petitprez F, Zhang J, Baumbach J, Fridman W . Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology. Bioinformatics. 2019; 35(14):i436-i445. PMC: 6612828. DOI: 10.1093/bioinformatics/btz363. View

15.

Kabbarah O, Nogueira C, Feng B, Nazarian R, Bosenberg M, Wu M . Integrative genome comparison of primary and metastatic melanomas. PLoS One. 2010; 5(5):e10770. PMC: 2875381. DOI: 10.1371/journal.pone.0010770. View

16.

Godec J, Tan Y, Liberzon A, Tamayo P, Bhattacharya S, Butte A . Compendium of Immune Signatures Identifies Conserved and Species-Specific Biology in Response to Inflammation. Immunity. 2016; 44(1):194-206. PMC: 5330663. DOI: 10.1016/j.immuni.2015.12.006. View

17.

Weber J, DAngelo S, Minor D, Hodi F, Gutzmer R, Neyns B . Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015; 16(4):375-84. DOI: 10.1016/S1470-2045(15)70076-8. View

18.

Sheng Y, Yanping C, Tong L, Ning L, Yufeng L, Geyu L . Predicting the Risk of Melanoma Metastasis Using an Immune Risk Score in the Melanoma Cohort. Front Bioeng Biotechnol. 2020; 8:206. PMC: 7136491. DOI: 10.3389/fbioe.2020.00206. View

19.

Carney E . Nephrotic syndrome: Novel monogenic causes of Galloway-Mowat syndrome. Nat Rev Nephrol. 2017; 13(11):661. DOI: 10.1038/nrneph.2017.130. View

20.

Jonsson G, Busch C, Knappskog S, Geisler J, Miletic H, Ringner M . Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome. Clin Cancer Res. 2010; 16(13):3356-67. DOI: 10.1158/1078-0432.CCR-09-2509. View